GSK, iTeos Therapeutics to co-develop and co-commercialise cancer drug
TIGIT, a part of the CD226 checkpoint axis, has shown potential as a promising target for the next generation of immuno-oncology therapies based on preclinical data and a
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II (MPS II), also called Hunter syndrome.
Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).